Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Exact Sciences Co. (NASDAQ:EXASGet Free Report) have been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $95.40.

EXAS has been the subject of a number of research analyst reports. TheStreet downgraded shares of Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday, February 26th. William Blair restated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. BTIG Research decreased their price objective on Exact Sciences from $85.00 to $80.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th. Citigroup lowered their target price on Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Finally, Canaccord Genuity Group cut their price target on Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th.

Read Our Latest Stock Analysis on EXAS

Insider Buying and Selling

In other Exact Sciences news, insider Jacob A. Orville sold 2,154 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $59.32, for a total value of $127,775.28. Following the completion of the sale, the insider now owns 14,324 shares of the company’s stock, valued at $849,699.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Kevin T. Conroy sold 8,271 shares of Exact Sciences stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $59.32, for a total transaction of $490,635.72. Following the transaction, the chief executive officer now owns 1,299,496 shares in the company, valued at approximately $77,086,102.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jacob A. Orville sold 2,154 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $59.32, for a total value of $127,775.28. Following the sale, the insider now directly owns 14,324 shares of the company’s stock, valued at $849,699.68. The disclosure for this sale can be found here. Insiders have sold 25,921 shares of company stock valued at $1,572,497 in the last 90 days. 1.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Wolff Wiese Magana LLC raised its holdings in shares of Exact Sciences by 459.5% during the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after acquiring an additional 340 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in shares of Exact Sciences by 65.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 179 shares during the period. Able Wealth Management LLC bought a new stake in shares of Exact Sciences in the fourth quarter valued at about $45,000. Valley National Advisers Inc. boosted its position in shares of Exact Sciences by 29.5% during the third quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock worth $53,000 after buying an additional 176 shares during the period. Finally, Fortitude Family Office LLC acquired a new position in shares of Exact Sciences during the first quarter worth about $55,000. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Performance

Exact Sciences stock opened at $49.84 on Tuesday. The stock has a 50-day simple moving average of $61.94 and a 200 day simple moving average of $63.74. The stock has a market capitalization of $9.20 billion, a price-to-earnings ratio of -37.76 and a beta of 1.26. The company has a quick ratio of 1.45, a current ratio of 1.64 and a debt-to-equity ratio of 0.66. Exact Sciences has a 12-month low of $49.65 and a 12-month high of $100.77.

About Exact Sciences

(Get Free Report

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Stories

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.